Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Chemo, PBSC Rescue, and IL-2 for High Risk Acute Leukemia
NCT00008190Phase 2Completed
- Sponsor
- Herbert Irving Comprehensive Cancer Center
- Start
- Mar 1999
- Primary completion
- Nov 2005
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in acute leukemia, sponsored by Herbert Irving Comprehensive Cancer Center. Primary endpoint: Relapse-free survival. Started Mar 1999; status: completed.
02
Drugs
aldesleukin
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT00008190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00008190.